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Effect of cyclosporin A on renal function and kidney growth in the
uninephrectomized rat. This study was designed to characterize the
effect of cyclosporin A (CsA) on renal function and compensatory
kidney growth in a rat model of uninephrectomy (Ux). The infusion of
CsA (12.5 mg/k body wt) after acute Ux resulted in a fall in glomerular
filtration rate (GFR) and renal plasma flow (RPF) and a marked increase
in renal vascular resistance (RVR). Three weeks following Ux, GFR
was also reduced in CsA treated animals as compared to pair-fed
controls (0.39 0.03 vs. 0.67 0.06 ml/min/l00 g, P < 0.001), but RPF
was not (1.97 0.14 vs 2.19 0.34 ml/min/l00 g). The reduction in
GFR seen in rats treated with CsA was fully reversible two weeks after
discontinuation of the drug. Three weeks after Ux, kidney weight in
CsA-treated animals increased to the level of pair-fed controls (1.50
0.05 vs. 1.57 0.06g) but renal cortical RNA (39.4 4.3 vs. 49.3 1.3
jgIm1, P < 0.05), DNA (26.4 1.7 vs. 34.7 2.1 .tg/ml, P < 0.01), and
protein content (6.4 0.3 vs. 7.8 0.2 mg/dl, P < 0.001) were all
markedly reduced. Unilateral renal denervation in CsA-treated rats
resulted in an increase in GFR and RPF as compared to that of pair-fed
sham-denervated animals also treated with CsA (0.57 0.06 vs. 0.39
0.03 mI/minIlOO g, P <0.025 and 2.14 0.14vs. 1.63 0.20 ml/min/l00
g, P < 0.025, respectively). We conclude that the reduction in GFR
associated with the chronic administration of CsA in the Ux rat can
occur despite unchanged RPF, is reversible, and is ameliorated by renal
denervation. The finding of reduced cortical RNA and DNA content in
Ux rats treated with CsA indicate that both renal hypertrophy and
hyperplasia may be obliterated with the chronic use of this drug.
Various patterns of renal dysfunction have been described in
humans [1—81 and experimental animals [9—20] treated with
CsA. Contrary to early reports portraying CsA as a primary
tubular toxin [91, there is now increasing evidence that even
exceedingly large doses of CsA cause only mild tubule cell
injury in the rat [19, 20]. When administered acutely, or for
short periods of time, reductions in renal plasma flow (RPF) and
glomerular filtration rate (GFR) which are reversible and
roughly dose-dependent have been consistently demonstrated
[10—15]. These renal hemodynamic effects, in general, have
been ascribed to an increase in renal vascular resistance (RVR)
[10, 111. Progression to some degree of chronic renal insuffi-
ciency has been described with the prolonged use of CsA [2, 3].
The impact of chronic CsA administration on renal function
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in uninephrectomized animals and its impact on the compensa-
tory kidney growth that occurs following removal of renal mass
has not been well characterized. It is well known that following
uninephrectomy (Ux) whole-kidney GFR and kidney weight
increase in proportion [2 1—27]. By causing a decline in renal
perfusion, CsA could obliterate the increase in GFR expected
after Ux and thereby attenuate renal compensatory growth. In
a preliminary communication we concluded that, despite re-
duced GFR, CsA does not interfere with compensatory kidney
growth because kidney weight gain following Ux was unaf-
fected by the administration of this drug [281. Other investiga-
tors, however, have reported that compensatory kidney growth
following Ux is impaired by CsA at larger doses than used by us
[29—31]. CsA-treated rats do not gain body weight normally and,
in fact, experience weight loss when high doses of this agent are
administered for several days or weeks [29, 30, 32]. Accord-
ingly, the impairment in kidney weight gain following Ux noted
in these previous reports [29—31] may have been due, wholly or
in part, to impaired body weight gain owing to suppressed food
intake rather than to a renal effect(s) of CsA. The present study
examined the effect of CsA on the adaptive increase in kidney
function and its effect on biochemical parameters of compen-
satory kidney growth following Ux using controls strictly
pair-fed with CsA-treated animals.
CsA, when infused acutely, has been shown to activate
afferent and efferent renal nerves, and renal denervation has
been shown to reverse the reduction in renal blood flow (RB F)
and GFR caused by the drug [10, 11, 33, 34]. These findings
prompted us to examine whether unilateral renal denervation
protects against the reduction in GFR caused by CsA in a
chronic model of Ux. We employed this model to mimic the
clinical setting prevailing following the transplantation of a
renal allograft that by nature is denervated.
Methods
Experimental groups
Male Sprague-Dawley rats of approximately seven weeks of
age were selected for study. A total of 126 rats were divided into
12 experimental groups (Table 1). Groups I and II were utilized
for acute clearance studies. Animals received a regular rat diet
with tap water ad libitum up to the day of study. On the day of
study, both groups of rats underwent a right nephrectomy.
Renal clearance studies were begun one hour after surgery was
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Table 1. Experimental groups
N Food intake Type of study Drug
Group I 8 Ad libitum Clearance after acute Ux Vehicle i.v.
Group II 9 Ad libitum Clearance after acute lJx CsA i.v.
Group III 5 Ad libitum Clearance after chronic Ux Vehicle i.p. x 3 wks
Group IV 16 Ad libitum Clearance after chronic Ux CsA i.p. x 3 wks
Group V 13 Pair-fed with IV Clearance after chronic Ux Vehicle i.p. x 3 wks
Group VI 11 Pair-fed with VIII RNA, DNA after chronic sham Ux Vehicle i.p. x 3 wks
Group VII 11 Pair-fed with VIII RNA, DNA after chronic Ux Vehicle i.p, x 3 wks
Group VIII 10 Ad libitum RNA, DNA after chronic Ux CsA i.p. X 3 wks
Group IX 13 Pair-fed with X Clearance after chronic Ux (recovery) Vehicle i.p. x 3 wks
Group X 13 Ad libitum Clearance after chronic Ux (recovery) CsA i.p. x 3 wks
Group XI 7 Ad libitum Clearance after chronic Ux -- sham Dx CsA Lp. x 3 wks
Group XII 10 Pair-fed with XI Clearance after chronic Ux + Dx CsA i.p. x 3 wks
Abbreviations are: N, number of rats; Ux, uninephrectomy; Dx, denervation; vehicle was Liposyn® for studies involving i.v. infusion and
alcohol for those involving i.p. injections.
completed. Group I was given an intravenous infusion of a lipid
preparation (Liposyn, Abbott, Illinois, USA) at a rate of 2
cc/hr, whereas Group II received an intravenous infusion of
CsA (12.5 mg/k body wt) diluted with 2 cc of Liposyn. Two
baseline collections were obtained before administration of CsA
or vehicle. Upon completion of one hour of CsA or vehicle
infusion, two additional, 30-minute clearance collections were
completed.
For chronic studies, Groups III, IV, V, VII, VIII, IX, and X
underwent a right nephrectomy under light anesthesia. One
additional group of control animals (Group VI) underwent sham
nephrectomy of the right kidney. After surgery the animals
were returned to their cages until they were studied three weeks
later. Groups IV, VIII, and X received a daily intraperitoneal
(i.p.) injection of CsA (12.5 mg/k body wt) dissolved in 47.5%
alcohol, whereas Groups III, V. VI, VII, and IX received an
i.p. injection of 0.3 cc of vehicle (47.5% alcohol). Except for
Group III animals, which received food ad libitum, all the other
control groups were strictly pair-fed with their CsA-treated
counterparts. At the end of the three weeks, Groups III, IV,
and V were used for clearance studies, whereas Groups VI,
VII, and VIII were sacrificed and the left kidney used for
determinations of RNA, DNA, and protein content.
Groups IX and X were treated as Groups V and IV, respec-
tively, except that clearance studies were performed two weeks
after discontinuation of CsA vehicle or CsA, respectively.
Groups XI and XII underwent a right nephrectomy and, in
addition, underwent either a sham denervation procedure or a
surgical renal denervation of the left kidney, respectively. Both
groups were pair-fed while receiving CsA for 21 consecutive
days.
Surgical procedures
Unilateral nephrectomy of the right kidney was performed
via a flank incision under light anesthesia (nembutal 35 mg/k
body wt i.p.) by ligating the renal pedicle and removing the
kidney. Sham nephrectomy consisted of briefly exposing the
right kidney through a flank incision. For renal denervation, the
left kidney was exposed via a flank incision, the adventitia of
the renal artery was stripped away and all visible nerves
transected with the use of forceps under microscopic visualiza-
tion. The artery and vein were then wrapped with cotton soaked
in a solution of 10% phenol in absolute alcohol for two ten
minute periods, to destroy any remaining nerve fibers. This
procedure results in a 90% decrease in whole kidney tissue
norepinephrine levels measured two weeks following denerva-
tion (LaPointe M, Doctoral Thesis). Further evidence for
effective renal denervation was derived from the marked in-
crease in sodium excretion (Results, Table 6). The rats were
allowed to regain consciousness and returned to their cages
until studied. Sham denervated kidneys from Ux animals were
treated exactly like those of the denervated rats except that the
renal artery and vein were kept intact and normal saline was
used instead of phenol.
Clearance studies
On the day of study, the animals were anesthesized with
Inactin (10 mg/l00 g body wt i.p.; Promonta, FRG). Tracheos-
tomy was performed, and one carotid artery and jugular vein
were cannulated. The bladder was catheterized through an
abdominal incision. At the start of the experiment, 1125 lothala-
mate diluted in saline (0.75 fCi/ml) was infused at a rate of 0.024
mI/mm throughout the course of the experiment as a marker of
GFR. The rate of saline infusion was 4.4 mllhr. Chemical
p-aminohippurate (PAH) (Merck Sharp & Dohme, West Point,
Pennsylvania, USA) calculated to produce plasma levels be-
tween 1.5 and 3.0 mg/dl was given i.v. at a priming dose of 3.6
mg followed by a constant infusion (3.6 mg/hr) so as to maintain
stable plasma levels. At the conclusion of the experiment, a
sample of blood was obtained from the renal vein to calculate
the PAH extraction ratio. RBF was calculated as RPF/1 —
Hematocrit. RVR was calculated as mean blood pressure (BP)
divided by RBF.
Biochemical growth profile
Animals in Groups VI, VII, VIII were sacrificed with an
overdose of pentobarbital (70 mg/k body wt). The kidney was
then perfused with 50 ml of phosphate buffered saline contain-
ing 1 U/mI of RNAse inhibitor. After perfusion, the kidney was
removed and dissected to separate the cortex and medulla. The
cortical and medullary portions were weighed and placed in
vials containing 10 ml of sucrose-TKM buffer for homogeniza-
tion (Brinkman Kinematica homogenizer) for 10 seconds. Tis-
sue homogenates were kept at —20°C until assayed. Protein was
measured using the biuret method [351. DNA and RNA were
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Table 2. Acute studies in uninephrectomized rats
GFR RPF
BP
mm/lOU g FF mm Hg
RBF
mi/mm/IOU g
RVR
mm Hg/mit
min/100 gmi!
Control: Group I, N = 8
Baseline
P valuea
Vehicle
0.57 0.06
NS
0.49 0.07
2.09 0.26 0.30 0.04 99 7
NS NS NS
1.71 0.24 0.30 0.02 92 10
3.43 0.46
NS
2.73 0.39
7.52 1.09
NS
8.64 1.05
Experimental: Group II, N = 9
Baseline
P valuea
CsA
0.60 0.11
<0.01
0.26 0.03
2.18 0.37 0.32 0.06 98 4
<0.005 NS NS
0.75 0.16 0.44 0.07 85 5
3.56 0.60
<0.005
1.18 0.25
8.05 1.26
<0.02
26.50 6.49
Vehicle vs. CSAb <0.05 <0.005 <0.05 NS <0.005 <0.025
a Student (-test (paired analysis)b Student (-test (unpaired analysis)
Table 3. Chronic studies in uninephrectomized rats
Body wt Kidney wt GFR RPF liP
mi/mm/IOU g FF mm Hg
RBF
mh/minIlOO g
mmgml/
mm/IOU gg
Group IV 279 13
CsA, N = 16
P value NS
Group V pair-fed 265 10
controls, N = 13
1.54 0.09
NS
1.55 0.09
0.39 0.03 1.97 0.14 0.22 0.02 89 4
<0.001 NS <0.02 NS
0.67 0.06 2.19 0.34 0.35 0.05 100 7
3.03 0.24
NS
3.64 0.50
5.47 1.31
NS
5.70 1.32
a Student 1-test (unpaired data)
assayed as previously described [36, 37j. Data are expressed as
g!ml of homogenate.
Cyclosporin A was obtained in powder form from Dr. Winter
(Sandoz Ltd, East Hanover, New Jersey, USA). Statistical
analysis was performed by analysis of variance and using the
Student's t-test for paired and unpaired data as appropriate.
Data are presented as mean SEM. Statistical significance was
chosen at the P <0.05 level.
Results
Clearance studies after acute Ux
The infusion of CsA (12.5 mg/k body wt) to acutely unine-
phrectomized rats (Group II) resulted in a marked reduction in
GFR and RPF (Table 2). RBF decreased in association with a
large increase in RVR and a slight but not significant change in
mean systemic BP. The infusion of CsA vehicle (Group I) had
no significant effect on any of the renal hemodynamic parame-
ters studied. In CsA-treated rats GFR was reduced to about
53% of controls, whereas RPF was reduced to 44% of controls.
Consequently, filtration fraction (FF) was increased in the
group infused with CsA as compared to the group infused with
vehicle (0.44 0.07 and 0.30 0.02, P < 0.05). Both groups
had a similar total body weight (207 7.0 vs. 207 6.0 g) and
kidney weight (1.07 0.03 vs. 0.99 0.05 g).
Clearance studies after chronic Ux
Uninephrectomized rats treated with CsA (Group IV) gained
about the same body weight as pair-fed Ux controls receiving
CsA vehicle (Group V; Table 3). Daily food intake was similar
between the two groups (Fig. 1). Under these conditions, the
GFR of CsA-treated rats (Group IV) was reduced to 58% of that
of pair-fed controls (Group V), but neither RPF nor RBF were
significantly reduced. Consequently, FF was reduced in CsA-
treated rats. RVR and systemic BP were not significantly
different from those of pair-fed Ux controls. Despite their
reduced GFR, CsA-treated rats (Group IV) achieved a kidney
weight similar to that of pair-fed controls (Group V; Table 3).
Groups IV and V were further compared to an additional
control group of Ux rats which received CsA vehicle while
allowed food ad libitum (Group III). These animals ate consid-
erably more than CsA-treated animals allowed food ad libitum
(Group IV) or controls pair-fed with CsA-treated animals
(group V; Fig. 1). Consequently, their kidney weight and total
body weight were both increased as compared to CsA-treated
rats (Group IV) (2.17 0.14 vs. 1.54 0.09 g, P < 0.01 and 355
11 vs. 279 13 g, P < 0.02, respectively). In this control
group (Group III) RVR was markedly lower than Group IV
(1.36 0.06 vs. 5.47 1.3 mm Hg!mIIminhlOO g) while GFR and
RBF were markedly higher (0.72 0.04 vs. 0.39 0.03
mllmin/l00 g, P < 0.001 and 6.22 0.29 vs. 3.03 0.24
ml/min/l00 g, P < 0.001). The RBF and RVR of controls
pair-fed with CsA treated rats (Group V), however, were also
markedly different as compared to controls receiving food ad
libitum (3.64 0.50 vs. 6.22 0.29 ml!min/l00 g, P < 0.005)
and (5.70 1.32 vs. 1.36 0.06 mm Hg/mllmin/l00 g, P <
0.05), respectively. GFR was not significantly different between
these two control groups (0.67 0.06 vs. 0.72 0.04 ml!
min/100 g). The marked difference in RPF, RBF, and RVR
observed between the two control groups clearly reflected the
impact of food intake on these hemodynamic parameters. The
lack of a significant difference in GFR between the two control
groups clearly suggests that much of the fall in GFR noted in
12
£ 20
5)
C
00U-
Group VI
Sham-Ux,N=ll
P va1ue'
Group VII
Control-Ux,
N=11
P valuea
Group VIII
CsA-Ux,N = 10
Group VI vs. VIII
P valuea
One-way analysis
of variance
Body wt Kidney wt DNA RNA Protein
g
__________ug/mi j,rglml g/dl
244 7 1.11 0.04 25,4 2.0 41.3 1.6 6.1 0.2
<0.001 <0.005 <0.001 <0.001
240 8 1.57 0.06 34.7 2.1 49.3 1.3 7.8 0.2 1.48 0.10
NS <0.01 <0.05 <0.001
239 8 1.50 0.05 26.4 1.7 39.4 4.3 6.4 0.3 1.47 0.13
RNAJ
DNA RNA Protein DNA
gIml jsglml g/dl ratio
a Post-HOC comparison of groups following ANOVA using univariate F test
Group IV was due to CsA rather than a reduction in RPF
secondary to decreased food intake.
Biochemical markers of compensatory kidney growth after
chronic Ux
In chronically Ux rats treated with CsA (Group VIII), kidney
weight was not significantly different from that of pair-fed
controls treated with its vehicle (Group VII; Table 4). As
compared to animals that underwent a sham Ux procedure
(Group VI), kidney weight increased markedly in Groups VII
and VIII. As anticipated, control Ux rats receiving CsA vehicle
(Group VII) had a significantly higher renal cortical DNA, RNA
and protein content than those of sham-operated control ani-
mals (Group VI; Table 4). The renal cortical DNA, RNA, and
protein content of Ux rats treated with CsA (group VIII),
however, was not significantly different from those of sham Ux
rats (Group VI) and was significantly lower than those of
control Ux animals (Group VII). In the medulla there was a
similar trend as in the cortex. Only the difference in protein
content between groups VI and VII, however, achieved statis-
tical significance.
Clearance studies after discontinuation of GsA administration
Two weeks after the discontinuation of the administration of
CsA (Group X) or its vehicle (Group IX) neither GFR nor RPF
were different between the two groups (Table 5). Kidney weight
also was not significantly different between these two groups.
For comparison, the data of these two groups of Ux rats are
displayed together with those from animals studied immediately
after uninephrectomy (Groups I and II) and three weeks follow-
ing uninephrectomy (Groups III and V; Fig. 2). Chronic admin-
istration of CsA had a significant inhibitory effect on GFR and
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30
10
0
NX
Fig. 1. Daily food intake in rats treated with
CsA and pair-fed controls following Ux. After
________________________________________________________________________
recovery from Ux both groups ate much less
1 I I I than a control group of animals allowed food
3 5 7 9 11 13 15 17 19 21 ad libitum. Symbols are: (S) Ux + V ad
T d libitum (Group III); (A) Ux + V (Group V);me, 8YS (0) Ux + CsA (Group IV).
Table 4. Compensatory kidney growth
Cortex
RNA/
DNA
ratio
Medulla
1.69 0.11 13.0 1.4 24.7 4.7 2.1 0.1 2.40 0.24
NS
16.3 1.6 31.2 2.2 2.7 0.2 2.09 0.26
17.3 2.8 30.9 3.0 2.5 0.3 1.96 0.13
<0.001 NS NS NS
<0.001 <0.01 <0.05 <0.001 NS NS NS NS NS
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Table 5. Recovery series
Body wt .Kidney wt GFR RPF
FF
BP
mm Hg
RBF
ml/min/100 g
RVR
mm Hg!
ml/min/100 gg mI/mm /100 g
Group IX Controls, 278 17 1.62 0.15 0.52 0.03 1.89 0.19 0.29 0.02 104 5 3.00 0.27 5.48 0.84N = 13
P valuea NS NS NS NS NS NS NS NS
Group X CsA, 301 27 1.73 0.19 0,54 0.04 1.67 0.23 0.43 0.09 94 7 2.56 0.37 9.27 3.25
N = 13
a Student t-test (unpaired data)
3 weeks 5 weeks
(recovery)
Time after Nx
Fig. 2. Body weight, kidney weight, GFR, and RBF values in Ux rats
treated with GsA (0) or vehicle (•). At time 0 are represented Groups
I and II which were studied after acute Ux. At 3 weeks are represented
Groups IV and V which were studied following chronic Ux. At 5 weeks
are represented Groups IX and X which were treated like Groups IV
and V, except that animals were studied 2 weeks following discontin-
uation of vehicle and CsA, respectively. The asterisk denotes a signif-
icant difference between CsA treated and control rats (* P < 0.05 CsA
vs. control). Note that a marked inhibitory effect of CsA on RBF was
apparent after acute but not chronic Ux.
this effect was reversible. CsA administration was associated
with a reduction in RPF on acute basis but not when given daily
for three weeks.
Clearance studies after chronic renal denervation
To examine if the suppressive effect of CsA on GFR was
mediated via stimulation of renal nerve activity, Ux rats were
studied three weeks following unilateral renal denervation
(Group XII) or sham denervation (Group XI; Table 6). Body
weight and systemic BP were not significantly different between
both groups of CsA-treated animals. Both GFR and RPF were
higher in the denervated group than in the sham operated group
so that FF was virtually identical between the two groups. RBF
was higher while RVR was lower in the denervated than in the
sham-denervated group. Renal denervated rats displayed a
greater urine flow and a higher sodium excretion rate than those
of sham denervated animals also treated with CsA. These
anticipated findings were ascribed, at least in part, to the well
known inhibitory effect of renal denervation on tubular fluid and
sodium reabsorption [38].
Discussion
Successful kidney transplantation is associated with adaptive
renal hemodynamic changes as well as a compensatory increase
in renal mass. These changes resemble, to a great extent, the
physiologic adaptation which occurs in the contralateral kidney
following unilateral nephrectomy. In the present study a rat
model of Ux was used to study the impact of CsA on these
adaptive processes.
When CsA was infused immediately following acute Ux, the
drug produced a rapid fall in the GFR of the contralateral
kidney and an even greater fall in RPF. Consequently, the renal
FF of CsA-treated animals was higher than that of Ux rats
infused with CsA vehicle. Insofar as systemic mean BP was not
significantly affected by CsA, the fall in RBF was largely the
consequence of an increase in RVR. These findings are, in
general, in agreement with previous studies in rats with intact
kidneys infused with comparable or higher doses of CsA
[10—15]. The adaptive increase in RPF and GFR in the contra-
lateral kidney begins immediately following Ux [22—26]. Our
data, therefore, suggest that these early compensatory events,
which are also expected after the implantation of a functioning
renal allograft, may be likewise blunted by the administration of
CsA.
When administered for three weeks, CsA also resulted in a
reduction in GFR as compared to pair-fed controls. Over this
extended period of time, however, CsA did not significantly
increase RVR and resulted in only a marginal reduction in RPF
which did not achieve statistical significance (Table 3). The lack
of a significant effect of CsA on RPF in our uninephrectomized
rats is in agreement with a recent study by Bertani et al [16] in
rats with intact kidneys that had received large doses of CsA for
one to five months. An inherent difficulty of all chronic studies
using CsA in the rat is that renal function cannot be assessed
under conditions of normal food intake. Reduction in food
intake is well known to exert a marked suppressive effect on
RPF as a result of diminished protein intake. This effect was
readily apparent in our control rats (Group V) in which food
0)
>-
0
300
260
220
180
0) 1.6
2.0
E 1.6
1.2U-
0.8
U-
6.0
5.0
4.0
3.0
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Table 6. Effect of unilateral renal denervation in uninephrectomized rats treated with CsA
RVR
Body wt Kidney wt
g
GFR RPF
mI/min!100 g FF
HP
mm
Hg
RBF
mi/mm/IOU g
mm Hg!
mi/mini
100 g
UNaXV
Eq/min/1OO g
V
ml/min/IOO g
Group XI 229 1.24 0.39 1.63 0.28 94 2.46 8.48 0.5! 0.004
Sham denervated, 18 0.13 0.03 0.20 0.05 2.5 0.32 1.16 0.10 0.001
N= 7
P valuea NS NS <0.025 <0.025 NS NS <0.01 <0.05 <0.005 <0.025
Group XII 279 1.52 0.57 2.14 0.28 93 3.36 4.02 1.55 0.008
Denervated, 21 0.17 0.06 0.14 0.04 3.9 0,17 0.53 0.14 0.001
N—tO
Abbreviations are: UNaxV, Na excretion; V, urine flow rate.
a Student's t-test (unpaired data)
intake was restricted to match that of CsA treated rats (Group
IV). The RPF, but not the GFR of these controls (Group V) was
markedly reduced as compared to controls receiving food ad
libitum (Group III). Insofar as the GFR of the two control
groups was not significantly different from each other, the low
GFR of CsA-treated rats (Group IV) appears clearly indepen-
dent of an effect of RPF secondary to decreased food intake. It
is likely that if the RPF of CsA-treated rats were not already
reduced as a consequence of diminished food intake, an inhib-
itory effect of CsA on RPF would be readily apparent on a
chronic basis as it is when the drug is given acutely (Table 2).
Food intake in humans, to our knowledge, is not reduced to any
discernible degree by the administration of CsA and, in this
setting, effective RPF is usually reduced [2, 31. Our data
nevertheless demonstrate that, at hast under conditions of
reduced food intake, CsA is capable of reducing GFR indepen-
dently of a reduction in RPF.
Despite its protracted administration for 21 consecutive days,
the inhibitory effect of CsA on GFR was fully reversible when
this parameter was measured two weeks after discontinuation
of the drug. This suggests that even after a prolonged period of
exposure to the drug much of its suppressive effect on GFR is
functional rather than due to permanent structural damage.
Our data demonstrate that CsA interferes with the compen-
satory increase in kidney growth that follows removal of renal
mass. This is shown by the findings of reduced protein, RNA,
and DNA content in Ux rats treated with CsA as compared to
pair-fed Ux animals receiving CsA vehicle. The impact of CsA
on compensatory kidney growth was pronounced as judged by
the fact that renal cortical protein, RNA, and DNA content
were not increased above the values found in sham Ux animals.
In sharp contrast, kidney weight in Ux animals treated with
CsA increased to a value similar to that of pair-fed Ux controls.
Thus, if kidney weight gain is used as a criterion, the compen-
satory increase in renal mass following Ux appears unaffected
by CsA as we reported in a preliminary communication [281.
Kidney weight, however, reflects not only changes in renal
mass but also changes in water content. An increase in renal
water content in CsA-treated kidneys, as compared to pair-fed
controls, may account for the lack of a reduction in kidney
weight gain despite reduced renal cortical RNA, DNA, and
protein content. In keeping with this possibility, significant
extravasation of plasma from the vascular into the interstitial
space has been reported in rats treated with a dose of CsA
comparable to that employed in the present study [391. A shift
of vascular fluid into the interstitial space may be caused by a
reduction in plasma protein which has also been documented
after one week of CsA treatment [9, 39]. An even greater
depression in plasma protein should be expected over a more
prolonged period of administration such as that employed by
us. Interstitial accumulation of fluid would also be in keeping
with various studies showing reduced plasma volume in CsA-
treated rats [391, and renal transplant recipients [40].
For comparison purposes, it is worthwhile noting that when
compared to Ux control rats in which food intake was not
restricted (Group III), the kidney weight of CsA-treated rats
(Group IV) was frankly diminished. That this reflected the
marked difference in food intake between these two groups is
clearly suggested from the finding that control Ux rats pair-fed
with Ux CsA-treated rats (Group V) also displayed a similar
blunting of the increase in kidney weight. Accordingly, an
inhibitory effect of CsA on food intake rather than a renal
effect(s) of the drug explains, at least in part, the impairment in
kidney weight gain following Ux reported in studies performed
without strict pair-feeding [29, 30]. Our data, therefore, suggest
that under certain circumstances kidney weight does not accu-
rately portray compensatory kidney growth.
The biochemical profile seen the first few days following Ux
is characterized by an early increase in RNA and a delayed
increase in DNA so that the RNAIDNA ratio is increased [24,
41—43]. After two weeks following Ux the RNA/DNA ratio may
be normal because RNA synthesis reaches a peak after three to
four days, whereas DNA synthesis may continue to increase
beyond this point [41, 42]. In control rats studied three weeks
following Ux both renal cortical RNA and DNA content were
increased as compared to sham operated animals, thereby
suggesting an increase in both renal hypertrophy and hyperpla-
sia. Our finding of failure of CsA-treated rats to increase either
renal cortical RNA or DNA content three weeks following Ux
indicates that CsA interferes with both renal hypertrophy and
hyperplasia. It is likely that in earlier stages following Ux the
RNA/DNA ratio is reduced by CsA, reflecting a preferential
impairment of the hypertrophic response as reported by Logan
and Benson [31].
The physiologic basis of the inhibitory effect of CsA on
compensatory kidney growth may very well be hemodynamic.
An elevation in GFR is viewed by some authors [26] as a
necessary requirement for the initiation of compensatory renal
growth following Ux. According to this view, CsA may have
blunted compensatory kidney growth following unilateral ne-
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phrectomy by virtue of its rapid and sustained inhibitory effect
on GFR. The possibility of a direct effect on CsA on kidney
growth independent or additional to that expected on the basis
of its inhibitory effect on GFR, however, needs to be consid-
ered as well. In the view of some authors [22, 23], compensa-
tory kidney growth after Ux is largely independent of GFR and
RBF. Katz, Toback and Lindheimer [23] showed that kidney
growth may precede the increase in GFR in the first 24 hours
following uninephrectomy. Further, F14[C] choline incorpora-
tion into phospholipid of renal cortical slices, a sensitive marker
of the onset of kidney growth, was found to be increased
following Ux despite a reduction in GFR imposed by elevation
of ureteral pressure [23]. Thus, while our finding of decreased
RNA, DNA, and protein content in renal cortex could be due to
inhibitory effect of CsA on renal growth secondary to reduced
GFR, we cannot exclude a more direct inhibitory effect(s) of
CsA on renal growth. Of note in this regard is the finding that
CsA diminishes the renal activity of ornithine decarboxylase,
the rate-limiting step in the synthesis of polyamines, a class of
growth-regulating compounds involved in renotropic action
[44]. CsA has also been shown to inhibit endothelial cell
replication [45].
Finally, our data show that in Ux animals treated with CsA,
unilateral renal denervation results in amelioration of GFR as
compared to Ux animals also treated with CsA that did not
undergo renal denervation. The improvement in GFR afforded
by renal denervation was associated with an increase in RBF
and a reduction in RVR. This is consistent with previous work
indicating that vasoconstriction of the afferent arteriole as a
result of a stimulatory effect of the drug on sympathetic tone
[11] and/or other hormonal effects [18, 46, 47] contributes
importantly to its suppressive effect on renal function. Further,
a recent study by Thomson et al [34] in intact rats treated with
CsA for one week disclosed a reduction in single nephron GFR
which was not associated with reduced glomerular capillary
ultrafiltration coefficient (Kr). These authors found that renal
denervation improved single nephron GFR via increases in
single nephron plasma flow and transglomerular pressure.
An effect of CsA on GFR mediated via an effect on Kf,
however, is also likely. A recent micropuncture study has
shown that CsA not only increases afferent renal arteriole
resistance but it markedly reduces Kf [151. The action of CsA
on K may be due to a reduction in glomerular ultrafiltration
area as a result of increased mesangial cell contraction [48, 49].
This is further suggested by the finding that CsA enhances
vasopressin-mediated mesangial cell contraction in association
with an increase in free cytosolic Ca2 [49]. Conceivably, an
increase in free cytosolic Ca2 could also mediate mesangial
cell contraction in response to CsA-induced renal nerve over-
activity, thereby causing a decrease in Kf. Consistent with this
notion is the micropuncture work of Kon and Ichikawa [50]
demonstrating a reduction in Kf during renal nerve stimulation.
Other authors, however, did not find an effect of renal nerves on
K [51). In our study, the improvement in GFR by renal
denervation occurred in association with an increase in RBF,
whereas intact rats displayed reduced GFR but normal RPF.
Thus, the mechanism by which renal denervation leads to
improved GFR does not need to be the mere reversal of the
mechanism that causes its reduction. Regardless of the mech-
anism(s) involved, the protective effect of renal denervation on
the GFR may have clinical implications. The protection af-
forded by chronic unilateral renal denervation is rather substan-
tial, as judged by the finding of a GFR only slightly lower than
that of controls not treated with CsA. This suggests that the
kidney allograft may be protected, for as long as it remains
denervated, against the component of CsA nephrotoxicity
dependent on sympathetic renal nerve overactivity. It may also
be anticipated that maneuvers that reduce sympathetic renal
activity (for instance, pharmacological intervention with a1
adrenergic blocking agents) could be of benefit in attenuating
CsA induced nephrotoxicity in individuals with intact kidneys.
In summary, the present investigation has characterized
some aspects of the impact of chronic CsA administration on
renal function in the Ux rat. It underscores the complexity and
disparity of the renal effects of CsA which may depend on the
duration of treatment, food intake, etc. As compared to pair-fed
controls, Ux rats treated with CsA for three weeks have
reduced GFR despite unchanged RPF. The inhibitory effect of
CsA on GFR is fully reversible and is ameliorated by renal
denervation at the time of contralateral nephrectomy. Rats
treated with CsA for three weeks have impaired compensatory
kidney growth as inferred from failure to increase renal cortical
RNA, DNA, and protein content following Ux. One implication
of our findings, if extrapolated to the clinical setting, is that
compensatory kidney growth after successful renal transplan-
tation may be abrogated by the continued administration of
CsA.
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